Urolithin A Supplement Reverses Age-Related Immune Decline in Middle-Aged Adults
Four-week trial shows mitophagy inducer urolithin A expands youthful T cells and improves immune metabolism in healthy adults aged 45-70.
Résumé
A randomized controlled trial of 50 healthy middle-aged adults found that urolithin A supplementation for just 4 weeks significantly improved immune function. The mitophagy-inducing compound expanded naive-like CD8+ T cells, enhanced cellular energy metabolism, and increased beneficial immune cell populations. Participants taking 1,000mg daily showed improved T cell fatty acid oxidation, increased mitochondrial biogenesis, and better immune cell activation responses. These findings suggest urolithin A could help counteract age-related immune decline and chronic inflammation that contribute to disease susceptibility in aging.
Résumé détaillé
Age-related immune decline, characterized by reduced naive T cells and chronic low-grade inflammation, increases vulnerability to infections, cancer, and age-related diseases. This groundbreaking study investigated whether urolithin A, a natural mitophagy inducer derived from pomegranates, could reverse these changes in humans.
Researchers conducted a randomized, double-blind, placebo-controlled trial with 50 healthy adults aged 45-70. Participants received either 1,000mg urolithin A or placebo daily for 28 days. The team analyzed immune cell populations, metabolic function, and inflammatory markers before and after treatment.
The results were striking. Urolithin A significantly expanded naive-like CD8+ T cells by 0.5 percentage points compared to placebo, representing a shift toward more youthful immune profiles. Even more impressive was the 14.7 percentage point increase in CD8+ T cell fatty acid oxidation capacity, indicating enhanced cellular energy metabolism. The supplement also increased beneficial immune populations including CD56dim CD16bright NK cells and nonclassical monocytes, while improving T cell activation responses and monocyte bacterial uptake.
Single-cell RNA sequencing revealed that urolithin A triggered widespread transcriptional changes across immune cell types, modulating inflammation and metabolism pathways. The compound enhanced mitochondrial biogenesis in CD8+ T cells, supporting the hypothesis that improved mitochondrial quality control drives these beneficial effects.
These findings suggest urolithin A could serve as a practical intervention for immune aging, potentially reducing disease risk and improving healthspan. The supplement was well-tolerated with no serious adverse events, supporting its safety profile established in previous trials.
Principales conclusions
- Urolithin A expanded naive-like CD8+ T cells by 0.5 percentage points in just 4 weeks
- CD8+ T cell fatty acid oxidation capacity increased by 14.7 percentage points
- Enhanced mitochondrial biogenesis and beneficial immune cell populations
- Improved T cell activation responses and monocyte bacterial uptake
- Single-cell analysis revealed widespread anti-inflammatory transcriptional changes
Méthodologie
Randomized, double-blind, placebo-controlled trial of 50 healthy adults aged 45-70 receiving 1,000mg urolithin A or placebo daily for 28 days. Primary outcomes measured T cell subset changes and immune metabolic remodeling using flow cytometry, functional assays, and single-cell RNA sequencing.
Limites de l'étude
Short 4-week duration limits assessment of long-term effects. Small sample size (n=50) and healthy participant population may not reflect broader applicability. Functional immune outcomes like vaccine responses or infection resistance were not measured.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :